サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1772231

米国のアレルギー診断・治療市場：市場規模・シェア・動向分析 (種類別・アレルゲンの種類別・検査の種類別)、セグメント別予測 (2025年～2030年)

U.S. Allergy Diagnostics & Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Allergen Type (Food, Inhaled, Drug, & Other Allergens), By Test Type, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 80 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
米国のアレルギー診断・治療市場：市場規模・シェア・動向分析 (種類別・アレルゲンの種類別・検査の種類別)、セグメント別予測 (2025年～2030年)
出版日: 2025年06月30日
発行: Grand View Research
ページ情報: 英文 80 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国のアレルギー診断・治療の市場規模は2024年に108億6,000万米ドルとなり、2025年から2030年にかけてCAGR 6.8％で成長すると予測されます。

この市場を牽引しているのは、人口の間でアレルギーの有病率が増加していることであり、公害の増加やライフスタイルの変化などの環境要因が高度なソリューションへの需要を押し上げています。米国のアレルギー診断・治療業界は、精密診断へのシフトを目の当たりにしています。この進化は、分子アレルギー学における画期的な技術革新とデジタルヘルスツールの普及によって後押しされています。

各社はアレルギー検査のポートフォリオを積極的に拡大しており、1検体から多数のアレルゲンを同時に検出できるマルチプレックス・アッセイに注力しています。さらに、これらの診断プラットフォームは、電子カルテ（EHR）とのシームレスな統合を目指した設計が増加しており、包括的な患者データ管理を容易にし、臨床上の意思決定を強化する重要な進歩となっています。

この業界は、継続的な研究開発、技術の進歩、より効果的な診断法や治療法の開発による高度なイノベーションを特徴としています。2025年4月、ベックマン・コールター・ライフサイエンス社は次世代好塩基球活性化検査（BAT）の発売を発表しました。これは、アレルギー研究を迅速化し、改善するための研究目的に限定されます。

米国のアレルギー診断・治療業界は、診断精度と治療効果の向上を重視し、主要企業間で多くの新規上市、戦略的提携、買収が行われていることも特徴です。2024年1月、Inimmune CorporationとIntrommune Therapeuticsは、ピーナッツアレルギーに対する画期的な経口粘膜免疫療法を開発するための戦略的提携を発表しました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 米国のアレルギー診断・治療市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 米国のアレルギー診断・治療市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析
  • 米国のアレルギー診断・治療市場：パイプライン分析

第4章 米国のアレルギー診断・治療市場：種類別の推定・動向分析

  • セグメントダッシュボード：種類別
  • 米国のアレルギー診断・治療市場：変動分析、種類別
  • 米国のアレルギー診断・治療の市場規模・動向分析：種類別（2018～2030年）
  • 診断
    • 機器
    • 消耗品
    • サービス
  • 治療
    • 抗ヒスタミン薬
    • 鼻づまり解消薬
    • コルチコステロイド
    • 肥満細胞安定剤
    • ロイコトリエン阻害剤
    • 鼻腔抗コリン薬
    • 免疫調節剤
    • エピネフリン
    • 免疫療法

第5章 米国のアレルギー診断・治療市場：アレルゲンの種類別の推定・動向分析

  • セグメントダッシュボード：アレルゲンの種類別
  • 米国のアレルギー診断・治療市場：変動分析、アレルゲンの種類別
  • 米国のアレルギー診断・治療の市場規模・動向分析：アレルゲンの種類別（2018～2030年）
  • 食品
    • 乳製品
    • 家禽製品
    • 木の実
    • ピーナッツ
    • 貝
    • 小麦
    • 大豆
    • その他の食物アレルゲン
  • 吸入
  • 薬剤
  • その他のアレルゲン

第6章 米国のアレルギー診断・治療市場：検査の種類別の推定・動向分析

  • セグメントダッシュボード：検査の種類別
  • 米国のアレルギー診断・治療市場：変動分析、検査の種類別
  • 米国のアレルギー診断・治療の市場規模・動向分析：検査の種類別（2018～2030年）
  • 生体内試験
    • 皮膚プリックテスト
    • 皮内テスト
    • パッチテスト
  • 生体外試験

第7章 競合情勢

  • 最近の動向と影響分析：主要企業別
  • 企業/競合の分類
  • ベンダー情勢
    • 主要企業のヒートマップ分析（2024年）
  • 企業プロファイル
    • Thermo Fischer Scientific Inc.
    • Stallergenes Greer
    • HYCOR Biomedical
    • Minaris Medical America, Inc.
    • Omega Diagnostics Ltd
    • Lincoln Diagnostics, Inc.
    • Danaher Corporation
    • Alcon Inc.
    • AbbVie Inc.
    • Sanofi
    • Pfizer Inc.
    • Merck &Co., Inc.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. allergy diagnostics & therapeutics market, by type, 2018 - 2030 (USD Billion)
  • Table 3 U.S. allergy diagnostics & therapeutics market, by allergen type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. allergy diagnostics & therapeutics market, by test type, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Allergy Diagnostics & Therapeutics market: market outlook
  • Fig. 10 U.S. Allergy Diagnostics & Therapeutics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Allergy Diagnostics & Therapeutics market driver impact
  • Fig. 16 U.S. Allergy Diagnostics & Therapeutics market restraint impact
  • Fig. 17 U.S. Allergy Diagnostics & Therapeutics market strategic initiatives analysis
  • Fig. 18 U.S. Allergy Diagnostics & Therapeutics market: type movement analysis
  • Fig. 19 U.S. Allergy Diagnostics & Therapeutics market: type outlook and key takeaways
  • Fig. 20 Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 21 Instrument market estimates and forecast, 2018 - 2030
  • Fig. 22 Consumable market estimates and forecast, 2018 - 2030
  • Fig. 23 Service market estimates and forecast, 2018 - 2030
  • Fig. 24 Therapeutics market estimates and forecast, 2018 - 2030
  • Fig. 25 Antihistamines market estimates and forecast, 2018 - 2030
  • Fig. 26 Decongestants market estimates and forecast, 2018 - 2030
  • Fig. 27 Corticosteroids market estimates and forecast, 2018 - 2030
  • Fig. 28 Mast cell stabilizers market estimates and forecast, 2018 - 2030
  • Fig. 29 Leukotriene inhibitors market estimates and forecast, 2018 - 2030
  • Fig. 30 Nasal anti - cholinergic market estimates and forecast, 2018 - 2030
  • Fig. 31 Immuno-modulators market estimates and forecast, 2018 - 2030
  • Fig. 32 Epinephrine market estimates and forecast, 2018 - 2030
  • Fig. 33 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 34 U.S. Allergy Diagnostics & Therapeutics market: allergen type movement analysis
  • Fig. 35 U.S. Allergy Diagnostics & Therapeutics market: allergen type outlook and key takeaways
  • Fig. 36 Food market estimates and forecasts, 2018 - 2030
  • Fig. 37 Dairy products market estimates and forecasts,2018 - 2030
  • Fig. 38 Poultry products market estimates and forecasts,2018- 2030
  • Fig. 39 Tree nuts market estimates and forecasts,2018 - 2030
  • Fig. 40 Peanuts market estimates and forecasts,2018 - 2030
  • Fig. 41 Shellfish market estimates and forecasts,2018 - 2030
  • Fig. 42 Soys market estimates and forecasts,2018 - 2030
  • Fig. 43 Other food allergens market estimates and forecasts,2018 - 2030
  • Fig. 44 Inhaled market estimates and forecasts,2018 - 2030
  • Fig. 45 Drug market estimates and forecasts,2018 - 2030
  • Fig. 46 Other allergens market estimates and forecasts,2018 - 2030
  • Fig. 47 U.S. Allergy Diagnostics & Therapeutics market: test type movement analysis
  • Fig. 48 U.S. Allergy Diagnostics & Therapeutics market: test type outlook and key takeaways
  • Fig. 49 North America market estimates and forecasts, 2018 - 2030
  • Fig. 50 In vivo test market estimates and forecasts, 2018 - 2030
  • Fig. 51 Skin prick test market estimates and forecasts, 2018 - 2030
  • Fig. 52 Intradermal market estimates and forecasts, 2018 - 2030
  • Fig. 53 Patch test market estimates and forecasts,2018 - 2030
  • Fig. 54 In vitro test market estimates and forecasts,2018 - 2030
目次
Product Code: GVR-4-68040-650-0

Market Size & Trends:

The U.S. allergy diagnostics & therapeutics market size was valued at USD 10.86 billion in 2024 and is projected to grow at a CAGR of 6.8% from 2025 to 2030. The market is driven by the increasing prevalence of allergies among the population, and environmental factors such as increased pollution and lifestyle changes boost the demand for advanced solutions. The U.S. allergy diagnostics & therapeutics industry has witnessed a shift toward precision diagnostics. This evolution is fueled by groundbreaking innovations in molecular allergology and the widespread adoption of digital health tools.

Companies are actively expanding their allergy test portfolios, focusing on multiplex assays that enable the simultaneous detection of numerous allergens from a single patient sample. Furthermore, these diagnostic platforms are increasingly designed for seamless integration with Electronic Health Records (EHRs), a critical advancement that facilitates comprehensive patient data management and enhances clinical decision-making.

The industry is characterized by a high degree of innovation driven by ongoing research, technological advancements, and the development of more effective diagnostics and treatment options. In April 2025, Beckman Coulter Life Sciences announced the launch of its Next-Generation Basophil Activation Test (BAT). It is only for research purposes to expedite and improve allergy research.

The U.S. allergy diagnostics & therapeutics industry is also characterized by many new launches, strategic collaborations, and acquisitions among key players, emphasizing enhancing diagnostic accuracy and therapeutic efficacy. In January 2024, Inimmune Corporation and Intrommune Therapeutics announced a strategic partnership to develop a groundbreaking oral mucosal immunotherapy for peanut allergy.

U.S. Allergy Diagnostics & Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. allergy diagnostics & therapeutics market report based on type, allergen type, test type.

  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Diagnostics
    • Instruments
    • Consumables
    • Services
  • Therapeutics
    • Antihistamines
    • Decongestants
    • Corticosteroids
    • Mast Cell Stabilizers
    • Leukotriene Inhibitors
    • Nasal Anti-cholinergic
    • Immuno-modulators
    • Epinephrine
    • Immunotherapy
  • Allergen Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Food
    • Dairy Products
    • Poultry Product
    • Tree Nuts
    • Peanuts
    • Shellfish
    • Wheat
    • Soys
    • Other Food Allergens
  • Inhaled
  • Drug
  • Other Allergens
  • Test Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • In vivo test
    • Skin Prick Test
    • Intradermal Test
    • Patch Test
  • In vitro test

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Allergen Type
    • 1.2.3. Test Type
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Allergen Type outlook
    • 2.2.3. Test Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Allergy Diagnostics & Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Allergy Diagnostics & Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Allergy Diagnostics & Therapeutics Market: Pipeline Analysis

Chapter 4. U.S. Allergy Diagnostics & Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. Allergy Diagnostics & Therapeutics Market: Type Movement Analysis
  • 4.3. U.S. Allergy Diagnostics & Therapeutics Market Size & Trend Analysis, By Type, 2018 To 2030 (USD Billion)
  • 4.4. Diagnostics
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Instruments
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Consumables
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Services
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Therapeutics
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2. Antihistamines
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3. Decongestants
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.4. Corticosteroids
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.5. Mast Cell Stabilizers
      • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.6. Leukotriene Inhibitors
      • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.7. Nasal Anti - Cholinergic
      • 4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.8. Immuno - Modulators
      • 4.5.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.9. Epinephrine
      • 4.5.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.10. Immunotherapy
      • 4.5.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Allergy Diagnostics & Therapeutics Market: Allergen Type Estimates & Trend Analysis

  • 5.1. Allergen Type Segment Dashboard
  • 5.2. U.S. Allergy Diagnostics & Therapeutics Market: Allergen Type Movement Analysis
  • 5.3. U.S. Allergy Diagnostics & Therapeutics Market Size & Trend Analysis, by Allergen Type, 2018 to 2030 (USD Billion)
  • 5.4. Food
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Dairy Products
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Poultry Product
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Tree Nuts
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Peanuts
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.6. Shellfish
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.7. Wheat
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.8. Soys
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.9. Other Food Allergens
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Inhaled
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Drug
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.7. Other Allergens
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Allergy Diagnostics & Therapeutics Market: Test Type Estimates & Trend Analysis

  • 6.1. Test Type Segment Dashboard
  • 6.2. U.S. Allergy Diagnostics & Therapeutics Market: Test Type Movement Analysis
  • 6.3. U.S. Allergy Diagnostics & Therapeutics Market Size & Trend Analysis, By Test Type, 2018 to 2030 (USD Billion)
  • 6.4. In vivo test
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Skin Prick Test
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Intradermal Test
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.4. Patch Test
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. In vitro test
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Thermo Fischer Scientific Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Type benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Stallergenes Greer
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Type benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. HYCOR Biomedical
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Type benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Minaris Medical America, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Type benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Omega Diagnostics Ltd
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Type benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Lincoln Diagnostics, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Type benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Danaher Corporation
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Type benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Alcon Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Type benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. AbbVie Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Type benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Sanofi
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Type benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Pfizer Inc.
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Type benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. Merck & Co., Inc.
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Type benchmarking
      • 7.4.12.4. Strategic initiatives